Plant extract supplement

Kanna (Sceletium tortuosum)

Kanna (Sceletium tortuosum) has been tested in randomized trials of 16 to 60 healthy adults, and the PubMed records found for human pharmacokinetics give no human half-life to set beside the app's 3 h.1,2

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Kanna (Sceletium tortuosum) after one dose: 50% at ~3 h, 25% at 6 h, 12.5% at 9 h.

Drawn from the half-life in the app's model, ~3 h. The model's figures

The app lists kanna (Sceletium tortuosum) as an oral supplement in the Mood Modulator sub-category. Terburg and colleagues (Neuropsychopharmacology, 2013) describe the plant as having a long history of traditional use as a masticatory and medicine by San and Khoikhoi people.1 Four of the five trials in the human studies table name Zembrin, a standardized extract; the fifth (Hoffman and colleagues) describes a 25 mg "ST extract".1,2 Terburg and colleagues describe the Zembrin active ingredient as a standardized and characterized aqueous ethanolic extract of the above-ground plant, and each 25 mg capsule in their trial was "equivalent to 50 mg of dry raw above-ground S. tortuosum plant material".1 Chiu and colleagues (Evidence-Based Complementary and Alternative Medicine, 2014) describe their extract as standardized to a total alkaloid content of 0.4% for the four main alkaloids.3 A 2026 review by de Jong and colleagues (Planta Medica; the authors declare no conflicts of interest) lists limitations of the published pre-clinical animal and clinical studies of M. tortuosum-derived products, including "small sample sizes and studies conducted in clinically irrelevant populations".4 The same review states that "not all studies showed consistent benefits".4 An earlier review (Olatunji and colleagues, Journal of Ethnopharmacology, 2021) states that "This plant has not yet been studied in a clinical population".5 The app grades the evidence for kanna as emerging; that grade is the app's own and not a conclusion of the sources. Terburg and colleagues report funds from H.L. Hall and Sons, Ltd, and the Netherlands Organization of Scientific Research, and Chiu and colleagues report support from HG&H Pharmaceuticals and PL Thomas & Co.1,3 Both papers name HG&H Pharmaceuticals as the company that developed the extract, and the registry entry for a Northumbria University trial lists HG&H Pharmaceuticals as a collaborator.1,3,6

The app describes kanna as a serotonin reuptake inhibitor and a PDE4 inhibitor. The sources behind that description are laboratory studies of the Zembrin extract and its alkaloids, not measurements of transporter or enzyme activity in people.7,1 Harvey and colleagues (Journal of Ethnopharmacology, 2011) tested a standardised Zembrin extract and three purified alkaloids on a panel of receptors, enzymes and other targets.7 They report that the extract "was a potent blocker in 5-HT transporter binding assays (IC(50) 4.3 μg/ml)".7 The extract also had "powerful inhibitory effects on phosphodiesterase 4 (PDE4) (IC(50) 8.5 μg/ml), but not other phosphodiesterases", and there were "no cytotoxic effects" in the cells tested.7 Among the purified alkaloids, mesembrine was the most active at the 5-HT transporter (Ki 1.4 nM), and mesembrenone was active against both the transporter and PDE4.7 The authors conclude that this activity "may explain the clinical effects of preparations made from this plant".7 Gericke and colleagues (Journal of Ethnopharmacology, 2024) treated zebrafish larvae (n = 12 per concentration) with Zembrin or single alkaloids and report that "Of all alkaloids assessed, only mesembrine contributed significantly to the anxiolytic-like effects of Zem".8 In that larval model "No alkaloid alone could be pinpointed as a contributor to the antidepressant-like activity observed for higher concentration Zem", and only the extreme concentration of 500 μg/mL elicited toxicity after 24 h.8 This is a fish larva model and not a human result; the authors declare no known competing financial interests.8

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~3 h
Bioavailability
60%
Typical dose
25–100 mg/day
Route
Oral
Time to peak
~1 h

The app's figures are a half-life of about 3 h, oral bioavailability of 60%, a time to peak of about 1 h and a duration of about 4 h. A PubMed query for Sceletium mesembrine pharmacokinetics in humans returned two records, a review (Olatunji and colleagues, 2021) and a metabolism study (Meyer and colleagues, 2015), and the record text of neither gives a human half-life, bioavailability or time to peak.5,9

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~3 hNo human half-life for Zembrin or its alkaloids appears in the PubMed records of the Olatunji review and the Meyer metabolism study, which were read as record text only5,9
Bioavailability60%No human oral bioavailability appears in the PubMed records of the Olatunji review and the Meyer metabolism study, which were read as record text only5,9
Time to peak~1 hNo measured time to peak appears in the sources read; Terburg and colleagues scanned participants at 2 h and Hoffman and colleagues tested at 2 h, which are testing times and not measured concentrations1,2
Duration~4 hNo measured duration of effect appears in the sources read1,2
MetabolismNot an app figureBoth alkaloids were O- and N-demethylated, dihydrated and/or hydroxylated and the phenolic metabolites were partly excreted as glucuronides and/or sulfates; metabolism was investigated in rat urine and pooled human liver preparations, and most of the phase I metabolites identified in rat urine were also detected in the human liver preparations9

Meyer and colleagues (Analytical and Bioanalytical Chemistry, 2015) report that most of the phase I metabolites seen in rat urine "could be detected also in the human liver preparations", and their monitoring proposal assumes similar pharmacokinetics in humans.9

4

Human studies

The table lists the five randomized trials in healthy volunteers and one registered trial with no posted results.

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Nell and colleagues, Journal of Alternative and Complementary Medicine, 201310Randomized, double-blind, parallel-group, placebo-controlled, single-centre safety and tolerability study; no efficacy variables assessed1037 healthy adults: 12 on 8 mg, 12 on 25 mg, 13 on placebo10Zembrin 8 mg or 25 mg once daily, 3 months10No apparent differences between the three treatments in vital signs, 12-lead ECG, body weight or physical examination; headache was the most commonly reported adverse event, with greater incidence in the placebo group than in the treatment groups10
Terburg and colleagues, Neuropsychopharmacology, 20131Double-blind, placebo-controlled, cross-over pharmaco-fMRI study; funded in part by H.L. Hall and Sons, Ltd116 healthy undergraduate students (eight female) aged 18–21 years; one excluded for below-chance task performance1Single 25 mg Zembrin dose, scanned 2 h later; sessions 5–9 days apart1Amygdala reactivity to fearful faces under low perceptual load was lower after Zembrin than placebo (F(1,14) = 6.90, P = 0.020) and not different under high load (P = 0.956); amygdala-hypothalamus connectivity was lower (8 voxels, P = 0.034); no drug effect in the whole-brain emotion-matching analysis1
Chiu and colleagues, Evidence-Based Complementary and Alternative Medicine, 2014 (NCT01805518)3,12Randomized, double-blind, placebo-controlled cross-over pilot, single centre in Puerto Rico; supported by HG&H Pharmaceuticals and PL Thomas & Co.321 healthy adults aged 45 to 65 entered (mean age 54.6 years); 2 dropped out in the placebo phase and 3 in the Zembrin phase; completer analysis3Zembrin 25 mg once daily for 3 weeks, 3-week washout, then the other treatment; 9 weeks in all3Executive function (60.8 after Zembrin, 50.1 after placebo; P = 0.032) and cognitive flexibility (60.2, 49.7; P = 0.022) were higher after Zembrin; the neurocognitive index was 43.9 after Zembrin and 47.2 after placebo and the memory domains did not differ significantly; Hamilton depression score change not significant; gastrointestinal discomfort 9.5% on Zembrin3
Reay and colleagues, Human Psychopharmacology, 202011Two placebo-controlled, double-blind, between-subject laboratory studies (multitasking stressor; simulated public speaking)1120 healthy volunteers across the two studies11Single 25 mg Zembrin dose11Study 1: no treatment effect; study 2: subjective anxiety significantly lower in the Zembrin group at the pre-stress point and a significant treatment by time interaction on heart rate11
Hoffman and colleagues, Journal of Strength and Conditioning Research, 20202Randomized, placebo-controlled; tests before supplementation and 2 h after the day-8 dose260 recreationally trained men (n = 48) and women (n = 12) aged 20 to 35 years225 mg Sceletium tortuosum extract, 8 days2Better performance on complex reactive tasks with a cognitive load than placebo; no significant between-group change in the visual analog scale or total mood score; no difference in simple reaction tests2
Registered trial NCT05471804 (Northumbria University, start 2022)6Randomized, double-blind, placebo-controlled, parallel-group; lead sponsor Northumbria University, collaborator HG&H Pharmaceuticals; status unknown, no results posted6Healthy adults aged 30 to 50625 mg per day of Zembrin for 8 weeks6Primary outcome: subjective stress on the Perceived Stress Scale; no result reported in the entry6

Deeper analysis: Terburg and colleagues, 2013 (amygdala fMRI)

Terburg and colleagues (Utrecht University and University of Cape Town, Neuropsychopharmacology, 2013) ran a double-blind, placebo-controlled, cross-over study in which each participant was scanned once after Zembrin and once after placebo.1 The 16 participants were healthy, medication-free undergraduates from the University of Cape Town.1 The dose was a single 25 mg Zembrin capsule, scanning took place at 2 h, and the primary measure was the fMRI response of the amygdala to fearful faces in a perceptual-load task and its connectivity during an emotion-matching task.1 One participant who performed below chance was excluded from both tasks.1 The drug by load by emotion interaction in the amygdala was significant (F(1,14) = 6.81, P = 0.028), driven by lower reactivity to fearful than neutral faces under low load (F(1,14) = 6.90, P = 0.020), with no effect under high load (P = 0.956).1 In the emotion-matching task there was no main effect of drug or interaction in the whole-brain analysis, and the amygdala signal showed a "marginally significant" interaction (P = 0.099) in the direction of stronger activity after Zembrin.1 Amygdala-hypothalamus connectivity was lower after Zembrin (8 voxels, P = 0.034), and the difference between the emotion and shape conditions was marginal (13 voxels, P = 0.068); the authors report no evidence of changed prefrontal-amygdala coupling.1 The authors write that "we did not observe general subjective mood effects".1 Participants were asked to report side effects, but the results sit in a supplementary table.1 The authors name as a caution that "we cannot separate these pharmacological actions in the present results", meaning serotonin reuptake and PDE4 inhibition.1 The authors also note that the behavioral data did not show the expected EMOTION × LOAD interaction, which they say is most likely due to a ceiling effect in low-load performance.1 The sponsor statement names H.L. Hall and Sons, Ltd, and the Netherlands Organization of Scientific Research; author N. Gericke is Director, Medical and Scientific Affairs, of HG&H Pharmaceuticals, the company that developed the extract, and another author (D.J.S.) reports grants or honoraria from several pharmaceutical companies.1

Deeper analysis: Chiu and colleagues, 2014 (cognition in healthy adults aged 45 to 65)

Chiu and colleagues (Lawson Health Research Institute and the University of Western Ontario, with HG&H Pharmaceuticals) report a randomized, double-blind, placebo-controlled cross-over pilot of 25 mg Zembrin once daily for 3 weeks, followed by a 3-week washout and 3 weeks of the other treatment.3 People aged 45 to 65 years were recruited by advertisement at one site in Puerto Rico, and those with psychiatric disorders on a structured interview or a Hamilton depression score at the exclusion threshold were excluded.3 The primary endpoint was cognitive change on the CNS Vital Signs computerized battery (nine domains plus an aggregate neurocognitive index), alongside safety and tolerability.3 Twenty-one people entered; two dropped out during the placebo phase and three during the Zembrin phase, and the analysis used completers, with 17 and 18 people in the two arms of the cognitive table.3 Executive function scored 36.8 at baseline, 60.8 after Zembrin and 50.1 after placebo (P = 0.032), and the authors report that cognitive flexibility was also significantly higher after Zembrin than placebo (P = 0.022).3 The neurocognitive index scored 43.9 after Zembrin and 47.2 after placebo, and the authors report no significant difference between the groups in composite, verbal or visual memory, attributing the fall in visual memory in both groups to a practice effect.3 On the Hamilton depression scale, scores moved from 2.17 to 1.22 on Zembrin and from 1.95 to 1.68 on placebo, and the authors state that "the difference failed to reach statistical significance".3 Table 2 of the same paper gives the Zembrin baseline as 1.67 (N = 18) rather than 2.17, and lists P = 0.075 and P = 0.289 beside the 26.9% and 13.8% changes.3 The authors call their sleep and mood findings "only preliminary" and say they "have to be interpreted with caution".3 For safety, the Zembrin group reported "transient gastrointestinal discomfort (9.5%) which resolved spontaneously", with no direct link ascribed by the clinician, no changes in blood pressure, pulse, temperature or weight in either group, and no life-threatening adverse events.3 Table 4 of the paper lists many other treatment-emergent events at a frequency of 5% or more in the Zembrin and placebo groups, and the text names the placebo group's common side effects as mild skin irritation (10%), appetite decrease (10%), weight loss (15%) and interrupted sleep (10%).3 The authors name their limitations as "small sample size, the short treatment period, and the single dosage".3 The analysis used a one-way ANOVA followed by a Tukey post hoc test on completers, the authors report no cross-over effect for either the placebo or the extract groups, and the PubMed summary and the results table assign the two P values to the two domains in different orders.3 Funding was from HG&H Pharmaceuticals and PL Thomas & Co. Inc., managed by Lawson Health Research Institute; author Gericke is Director, Medical and Scientific, of HG&H Pharmaceuticals and a trustee in a trust holding a minor shareholding in it, and author Badmaev was past Director of Medical and Scientific Affairs for PL Thomas, the North American distributor of Zembrin.3 The registry entry NCT01805518 names an individual investigator (Michel A. Woodbury, MD) as lead sponsor, PL Thomas & Co., Inc. as a collaborator, and a status of completed.12 The registry entry gives an enrollment count of 20, against 21 subjects entered in the paper.12,3

Deeper analysis: Nell and colleagues, 2013 (three-month safety trial)

Nell and colleagues (Tiervlei Trial Centre, Karl Bremer Hospital, Cape Town; Journal of Alternative and Complementary Medicine, 2013) ran the longest randomized exposure among the trials read, with the stated objective of evaluating the safety and tolerability of 8 mg and 25 mg of Zembrin once daily over three months.10 The trial took place between 2 February and 27 July 2009 and randomized 37 healthy adults, 12 to 8 mg, 12 to 25 mg and 13 to placebo.10 The authors state that "No efficacy variables were assessed".10 The authors report no apparent differences between treatments in vital signs, ECG, body weight or physical examination, and "No significant changes were observed in hematology or biochemistry parameters".10 Headache was the most commonly reported adverse event, followed by abdominal pain and upper respiratory tract infections, all with greater incidence in the placebo group than in the treatment groups.10 The authors conclude that both doses "were well tolerated when used by healthy human subjects once daily for 3 months".10 The PubMed record gives no funding statement, adverse event counts or limitations section; it lists Gericke N among the authors, and in the Terburg and Chiu papers an author named Nigel Gericke is described as a director at HG&H Pharmaceuticals.10,1,3

Other randomized trials and reviews

Reay and colleagues (Teesside and Northumbria Universities, Human Psychopharmacology, 2020) describe their results as "the first tentative behavioral evidence to support the anxiolytic properties" of 25 mg Zembrin, and only study 2 showed an effect on subjective anxiety and heart rate.11 The PubMed record for Reay and colleagues gives no funding statement; it lists Badmaev V of American Medical Holdings Inc. as an author, and group sizes are not stated in it.11 Hoffman and colleagues (Ariel University and Tel Aviv University, 2020) tested 25 mg for 8 days in people aged 20 to 35 and report that "no benefits in mood were observed" in that population, with better performance on complex reactive tasks that carry a cognitive load and no differences in simple reaction assessments.2 The PubMed record for Hoffman and colleagues gives no funding statement and no adverse event data.2 The registry entry for the Northumbria trial (NCT05471804) gives its overall status as unknown with a last known status of recruiting.6

5

Doses reported in studies and on labels

No DailyMed label for a Sceletium tortuosum product was returned by a search, so the table lists doses used in studies only.

Table 5.1Doses reported in studies and on labels7 rows
SourceDose and routeLengthPeople
The app's typical range25–100 mg/day, oralNot statedNot stated
Terburg and colleagues, 2013125 mg Zembrin, single doseSingle dose; scanned at 2 h16 healthy students
Nell and colleagues, 2013108 mg or 25 mg Zembrin once daily3 months37 healthy adults
Chiu and colleagues, 2014325 mg Zembrin once daily, oral capsule3 weeks per phase, 9 weeks in all21 healthy adults aged 45 to 65
Hoffman and colleagues, 2020225 mg Sceletium tortuosum extract8 days60 recreationally trained adults aged 20 to 35
Reay and colleagues, 20201125 mg Zembrin, single doseSingle dose20 healthy volunteers across two studies
Registered trial NCT05471804625 mg per day of Zembrin8 weeksHealthy adults aged 30 to 50

The highest daily amount in the trials above is 25 mg of extract, equivalent to 50 mg of raw above-ground plant material in the Terburg capsule, so none of the trials read used the upper end of the app's 25–100 mg/day range.1

The adverse events reported in the Nell and Chiu trials are given in the human studies table and the deeper analyses above; the records for Reay and colleagues and for Hoffman and colleagues give no adverse event data.10,3,11,2 In a rat study with an HG&H Pharmaceuticals author (Gericke N), Murbach and colleagues (Food and Chemical Toxicology, 2014) report "No mortality or treatment-related adverse effects" in male or female Wistar rats in 14-day and 90-day studies.13 The rat no-observed-adverse-effect levels were 5000 mg/kg bw/day (14 days) and 600 mg/kg bw/day (90 days), the highest doses tested, and these are animal results and not human safety data.13

7

Bloodwork and markers

The app lists no health markers to monitor for kanna. Nell and colleagues measured hematology, biochemistry and urinalysis at screening and at the end of three months of 8 mg or 25 mg Zembrin and report no significant changes.10 Chiu and colleagues report no changes in blood pressure, pulse, temperature or weight in either group over 9 weeks.3

8

Regulatory and anti-doping status

A search of the text of the WADA 2026 Prohibited List for "Sceletium", "kanna" and "mesembr" returned no match.14 The list states that "All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited" in S6, and several classes extend to "other substances with a similar chemical structure or similar biological effect(s)", so a name search is not a ruling on any product.14 A trade press report of 2 November 2026 says the Southern African Botanical Products Association announced that Sceletium tortuosum raw material "has achieved self-affirmed GRAS status in the United States for raw material use".15 The same report says the association is now seeking a similar self-affirmation for a generic sceletium extract.15 That item is an industry announcement and not an FDA document; no FDA, EMA or TGA document on kanna was identified in the searches run.15

No human half-life, bioavailability, time to peak or duration of effect for kanna alkaloids appears in the sources read (the Olatunji review and the Meyer metabolism study were read as PubMed record text only), so the app's figures of about 3 h, 60%, about 1 h and about 4 h have no figure from the sources beside them.5,9 The trials found in PubMed and ClinicalTrials.gov were in healthy volunteers, and no controlled trial in people with a diagnosed anxiety or depressive disorder was identified in those two searches; de Jong and colleagues list "studies conducted in clinically irrelevant populations" among the limitations of the published studies.4 The longest randomized exposure among the trials is 3 months at 8 mg or 25 mg, so longer-term effects in people are not described by these sources.10 Which of the reported actions, serotonin transporter blockade or PDE4 inhibition, produces any effect in people is not separated in the trials: Terburg and colleagues write that they "cannot separate these pharmacological actions", and in zebrafish larvae no single alkaloid accounted for the antidepressant-like activity.1,8 The trials used capsules of a standardized extract, and the sources do not describe studies of the traditional chewed, smoked or sniffed preparations.9

What is the half-life of kanna?

No human half-life for kanna or its alkaloids appears in the PubMed records of the Olatunji review and the Meyer metabolism study (record text only), and the app lists about 3 h.5,9 Meyer and colleagues studied the metabolism of mesembrine and mesembrenone in rat urine and pooled human liver preparations, not their half-life in people.9

What is the bioavailability of kanna?

No human oral bioavailability for kanna alkaloids appears in the PubMed records of the Olatunji review and the Meyer metabolism study (record text only), and the app lists 60%.5,9

How long does kanna take to peak?

No measured time to peak appears in the sources read, and the app lists about 1 h.1,2 Terburg and colleagues scanned participants 2 h after a 25 mg dose and Hoffman and colleagues tested at 2 h on day 8, which were testing times and not measured peaks.1,2

Is kanna banned by WADA?

A search of the text of the WADA 2026 Prohibited List for "Sceletium", "kanna" and "mesembr" returned no match.14 Several classes on the list also cover "other substances with a similar chemical structure or similar biological effect(s)", so the list's wording and not a name match decides any product.14

Does kanna inhibit serotonin reuptake and PDE4?

In laboratory assays a standardised Zembrin extract blocked the 5-HT transporter in binding assays (IC50 4.3 μg/ml) and inhibited PDE4 (IC50 8.5 μg/ml).7

Has kanna been tested in randomized trials?

Five randomized trials in healthy adults, with 16 to 60 participants each, are described above, all with the extract at 8 mg or 25 mg.1,10,3,11,2

What side effects were reported in kanna trials?

In a three-month trial of 8 mg and 25 mg Zembrin, headache was the most commonly reported adverse event and was more frequent on placebo than on Zembrin.10 In a three-week cross-over of 25 mg, gastrointestinal discomfort (9.5%) was reported on Zembrin and the clinician did not ascribe a direct link to Zembrin, Table 4 of the paper lists other events at 5% or more in both the Zembrin and placebo groups, and five of 21 participants dropped out.3

Did kanna improve cognition in trials?

In the cross-over trial of Chiu and colleagues, executive function (P = 0.032) and cognitive flexibility (P = 0.022) were higher after Zembrin than after placebo, while the authors report no significant difference in the memory domains.3 Hoffman and colleagues reported better complex reactive performance but no significant mood change after 8 days of 25 mg.2

12

References

  1. Terburg D, et al. Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Neuropsychopharmacology 2013. PMC3828542
  2. Hoffman JR, et al. Ergogenic effects of 8 days of Sceletium tortuosum supplementation on mood, visual tracking, and reaction in recreationally trained men and women. J Strength Cond Res 2020. PMID 32740286
  3. Chiu S, et al. Proof-of-concept randomized controlled study of cognition effects of the proprietary extract Sceletium tortuosum (Zembrin) targeting phosphodiesterase-4 in cognitively healthy subjects. Evid Based Complement Alternat Med 2014. PMC4217361
  4. de Jong M, et al. Mesembryanthemum tortuosum and Zembrin: mixed evidence from in vivo animal and clinical studies on their antidepressant and anxiolytic effects. Planta Med 2026. PMID 41771298
  5. Olatunji TL, et al. Sceletium tortuosum: a review on its phytochemistry, pharmacokinetics, biological and clinical activities. J Ethnopharmacol 2021. PMID 34333104
  6. Northumbria University. Psychological effects of 8 weeks supplementation with Sceletium tortuosum extract. ClinicalTrials.gov NCT05471804. NCT05471804
  7. Harvey AL, et al. Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. J Ethnopharmacol 2011. PMID 21798331
  8. Gericke J, et al. Sceletium tortuosum-derived mesembrine significantly contributes to the anxiolytic effect of Zembrin, but its anti-depressant effect may require synergy of multiple plant constituents. J Ethnopharmacol 2024. PMID 37660956
  9. Meyer GM, et al. Studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high "Kanna" isolated from Sceletium tortuosum. Anal Bioanal Chem 2015. PMID 25240931
  10. Nell H, et al. A randomized, double-blind, parallel-group, placebo-controlled trial of extract Sceletium tortuosum (Zembrin) in healthy adults. J Altern Complement Med 2013. PMID 23441963
  11. Reay J, et al. Sceletium tortuosum (Zembrin) ameliorates experimentally induced anxiety in healthy volunteers. Hum Psychopharmacol 2020. PMID 32761980
  12. Woodbury MA. Safety study of the effect of Scelectium tortuosum (as Zembrin) in aged normals. ClinicalTrials.gov NCT01805518. NCT01805518
  13. Murbach TS, et al. A toxicological safety assessment of a standardized extract of Sceletium tortuosum (Zembrin) in rats. Food Chem Toxicol 2014. PMID 25301237
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  15. Daniells S. This week's Nutraverse: Sceletium self-GRAS, Buck Institute-Oracle partnership, eimele's expansion plans. NutraIngredients, 2 November 2026. NutraIngredients article